Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis

Bone Marrow Transplant. 2015 Nov;50(11):1480-2. doi: 10.1038/bmt.2015.169. Epub 2015 Jul 27.

Authors

P Torka¹, T Hahn¹, J Bertolo¹, H Liu¹, M Ross¹, P Paplham¹, A Jankowski², G Deeb³, G Chen¹, P McCarthy¹

Affiliations

¹ Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
² Department of Hematology-oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
³ Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.

PMID: 26214139
DOI: 10.1038/bmt.2015.169

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Allografts
Chimerism
Clone Cells
Female
Hematopoietic Stem Cell Transplantation*
Humans
Janus Kinase 2 / genetics*
Middle Aged
Mutation, Missense
Myeloablative Agonists / pharmacology
Myeloablative Agonists / therapeutic use
Point Mutation
Primary Myelofibrosis / genetics
Primary Myelofibrosis / therapy*
Regeneration
Remission Induction
Retreatment
T-Lymphocytes, Cytotoxic / immunology
T-Lymphocytes, Cytotoxic / transplantation
Thrombocythemia, Essential / complications
Thrombocythemia, Essential / genetics

Substances

Myeloablative Agonists
JAK2 protein, human
Janus Kinase 2